Monitor for Phase 2 initiation in Q3 2026 and any subsequent data readouts. The cash runway into Q2 2027 reduces near-term financing risk but does not eliminate the need for future capital raises given the clinical-stage pipeline.
Price Chart
Executive Summary
Gain Therapeutics filed an 8-K announcing that its cash and cash equivalents are expected to fund operations into Q2 2027, including completion of the Phase 1b open-label extension in October 2026 and initiation of a Phase 2 study in Q3 2026. No specific cash balance or financial figures were disclosed—this is a routine cash runway and clinical timeline update.
Key Facts
- Cash runway expected to fund operations into Q2 2027.
- Phase 1b open-label extension completion expected in October 2026.
- Phase 2 clinical study initiation expected in Q3 2026.
- No specific cash balance or financial figures provided in the filing.
Financial Impact
Cash runway extended to Q2 2027, but no dollar amount disclosed. No revenue or earnings data provided.
Risk Factors
- Clinical trial execution risk (Phase 2 enrollment, data quality).
- Cash burn rate may require additional financing before Q2 2027 if operating plans change.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (GANX) — Batch item 1 | 0001104659-26-084086 |
| Document: 0001104659-26-084086-index-headers.html | 0001104659-26-084086 |
| Document: 0001104659-26-084086-index.html | 0001104659-26-084086 |
| Document: 0001104659-26-084086.txt | 0001104659-26-084086 |
| 8-K Filing (GANX) — Batch item 5 | 0001104659-26-084086 |
| Document: 0001104659-26-084086-index-headers.html | 0001104659-26-084086 |
| Document: 0001104659-26-084086-index.html | 0001104659-26-084086 |
| Document: 0001104659-26-084086.txt | 0001104659-26-084086 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 26d ago | Press Release | $1.72 $1.62 | ▼ −6.10% | ▼ −7.41% | $1.17 (−31.98%) |
Oct 1, 2026 26d ago | 8-K | $1.72 $1.62 | ▼ −6.10% | ▼ −7.41% | $1.17 (−31.98%) |
Aug 11, 2026 11w ago | Press Release | $2.06 $2.03 | ▼ −1.46% | ▼ −1.05% | $1.17 (−43.20%) |
Jul 16, 2026 14w ago | 8-K | $1.66 $1.82 | ▲ +9.64% | ▲ +11.31% | $1.17 (−29.52%) |
Jun 29, 2026 17w ago | 8-K | $2.03 $1.81 | ▼ −10.84% | ▼ −11.44% | $1.17 (−42.36%) |
Jun 29, 2026 17w ago | Press Release | $2.03 $1.81 | ▼ −10.84% | ▼ −11.44% | $1.17 (−42.36%) |
May 26, 2026 22w ago | 8-K | $1.82 $1.96 | ▲ +7.69% | ▲ +6.61% | $1.17 (−35.71%) |
May 11, 2026 24w ago | Press Release | $1.82 $1.62 | ▼ −10.99% | ▼ −10.90% | $1.17 (−35.71%) |
Apr 28, 2026 26w ago | DEFA14A | $1.76 $1.91 | ▲ +8.52% | ▲ +5.41% | $1.17 (−33.52%) |
Mar 26, 2026 30w ago | Press Release | $1.89 $1.85 | ▼ −2.12% | ▼ −3.75% | $1.17 (−38.10%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers